Flood of FDA Approvals Highlights SPT Week in Review

5. Sickle Cell Anemia Drug Gains FDA Approval

Treatment with hydroxyurea increased hemoglobin F levels for patients with sickle cell anemia. Read more.

4. FDA Greenlights Nivolumab as an Adjuvant Melanoma Therapy

Nivolumab (Opdivo) showed better tolerability than ipilimumab (Yervoy) in patients with metastatic melanoma.

Read more.

3. FDA Approves Pertuzumab for HER2+ Breast Cancer

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer. Read more.

2. Chronic Myelogenous Leukemia Drug Gains Accelerated Approval

Bosutinib (Bosulif) was approved by the FDA to treat patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia. Read more.

1. FDA Approves Gene Therapy for Rare Vision Loss Disease

Luxturna (voretigene neparvovec-rzyl) is indicated to treat confirmed biallelic RPE65 mutation-associated retinal dystrophy. Read more.